Document Detail


Management of benign prostatic hyperplasia by family physicians.
MedLine Citation:
PMID:  20170598     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The past decade has profoundly changed how physicians manage patients with benign prostatic hyperplasia (BPH). The concepts of symptom indices, symptom complexes, flow rates, prostate-specific antigen (PSA), prostate size and new medical approaches supported by new clinical studies, have provided family practitioners as well as specialists with evidence-based management algorithms to treat BPH. Men with BPH most often visit a physician due to their partner's urging because of the many symptoms, with the most bothersome being nocturia. Today, primary care physicians are the gatekeepers for diagnosing and managing lower urinary tract symptoms (LUTS) in men. They need to be aware of long term negative consequences if these major symptoms are not treated early.
Authors:
Allan Toguri; Jack Barkin
Related Documents :
20469478 - Family medicine in the undergraduate curriculum: differing views on where from here?
20469408 - Family medicine education in canada, 1983.
15812688 - Papaya: a simulation model for training in uterine aspiration.
7796898 - Are primary care residents adequately prepared to care for women of reproductive age?
19029108 - Feeding practices and the use of supplements for dogs kept by owners in different socio...
4812408 - Benorylate in management of still's disease.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Canadian journal of urology     Volume:  17 Suppl 1     ISSN:  1195-9479     ISO Abbreviation:  Can J Urol     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-22     Completed Date:  2010-05-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9515842     Medline TA:  Can J Urol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  26-34     Citation Subset:  IM    
Affiliation:
Department of Urology, Scarborough General Hospital, Scarborough, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic alpha-Antagonists / therapeutic use*
Aged
Combined Modality Therapy
Family Practice / methods*,  trends
Follow-Up Studies
Humans
Male
Middle Aged
Physicians, Family / trends
Prostate-Specific Antigen / blood*
Prostatic Hyperplasia / complications,  diagnosis,  therapy*
Risk Assessment
Severity of Illness Index
Transurethral Resection of Prostate
Treatment Outcome
Urinary Retention / diagnosis,  etiology,  therapy
Urination Disorders / etiology,  physiopathology,  therapy*
Urodynamics
Chemical
Reg. No./Substance:
0/Adrenergic alpha-Antagonists; EC 3.4.21.77/Prostate-Specific Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prostate-specific antigen tests and prostate cancer screening: an update for primary care physicians...
Next Document:  Uropharmacology in primary care: 2010 update.